180 Life Sciences Stock Price, News & Analysis
Company Description
ATNF historically represented 180 Life Sciences Corp. on the Nasdaq Capital Market. According to company disclosures, 180 Life Sciences began as an innovative biotechnology company and later pivoted its business toward the global interactive technology and iGaming sector, while retaining a portfolio of legacy biotechnology intellectual property assets. More recently, the company has further evolved by adopting an Ethereum (ETH) treasury strategy and rebranding to operate as ETHZilla, with plans for its stock to trade under the ticker ETHZ on Nasdaq, replacing ATNF.
The company describes itself as developing an accumulation vehicle for Ether (ETH), the native digital asset of the Ethereum blockchain. Through a treasury policy focused on ETH, it aims to hold Ether as the principal asset in its treasury reserve. Public disclosures explain that the company intends to allocate significant capital raised through private placements and convertible notes to purchase ETH and related yield-bearing assets, while also supporting its iGaming operations and working to monetize its legacy biotech intellectual property.
In connection with this strategy, the company has engaged Electric Capital as an external asset manager. Company statements describe plans for a differentiated, on-chain yield generation program that seeks to outperform traditional ETH staking by using a combination of staking, lending, liquidity provisioning and bespoke private agreements, subject to risk management. The company also refers to guidance from a DeFi Council composed of capital markets participants, Ethereum engineers, and decentralized finance founders, intended to help shape its treasury approach.
Alongside its digital asset treasury activities, the company has indicated that it is evolving its business toward software-enabled gaming and entertainment. It reports having acquired a proprietary Technology Gaming Platform described as a back-end system that allows operation of one or more online casinos. Public communications state that the company is focused on evaluating acquisitions or development of online casino and related entertainment businesses that would run on this platform, while it continues to refine and deploy its gaming initiatives.
Despite these pivots, 180 Life Sciences emphasizes the ongoing importance of its legacy biotechnology IP estate. Company announcements highlight patents and patent applications in therapeutic areas such as post-operative cognitive decline, neuroinflammation, and fibrosis. For example, the company has disclosed a Notice of Allowance from the United States Patent and Trademark Office for a patent application covering a method for preventing or reducing post-operative cognitive dysfunction using an anti-human tumor necrosis factor (TNF) alpha monoclonal antibody, and separate protection related to localized fibrotic disorders, including Dupuytren's Disease and Frozen Shoulder, through an IL-33 antagonist.
In more recent communications under the ETHZilla brand, the company states that it intends to focus a significant portion of its non-legacy operations on becoming an ETH accumulation vehicle built for the Ethereum community. It describes an ambition to become a benchmark for on-chain treasury management among public companies, while continuing to support its iGaming operations and seeking to realize value from its biotechnology intellectual property through potential partnering, licensing, or strategic transactions.
Investors researching ATNF should understand that this ticker is historically associated with 180 Life Sciences and its transition phases: from clinical-stage biotechnology, to a biotechnology company pivoting into iGaming, and then to a company implementing an Ethereum-focused treasury strategy and rebranding as ETHZilla. Company materials indicate that, as part of this evolution, the common stock and public warrants are expected to trade on Nasdaq under new symbols ETHZ and ETHZW, replacing ATNF and ANTFW.
Business evolution and segments
Based on company disclosures, the business can be viewed in three main areas:
- ETH treasury and digital asset strategy: Adoption of a treasury policy centered on Ether, use of proceeds from private placements and convertible notes to purchase ETH and yield-bearing assets, and collaboration with Electric Capital on on-chain yield strategies.
- Software-enabled gaming and iGaming: Focus on the global iGaming sector, leveraging a proprietary Technology Gaming Platform to operate or support online casino and related entertainment businesses, with attention to cryptocurrency and blockchain-related trends in gaming.
- Legacy biotechnology intellectual property: Maintenance and enhancement of a portfolio of biotech IP in areas such as anti-TNF therapies, post-operative cognitive decline, neuroinflammation, and fibrotic disorders, with stated intent to explore partnering, licensing, or other strategic options.
These activities reflect a company that has moved beyond its original biotechnology focus into digital entertainment and digital asset treasury management, while still emphasizing the potential value of its scientific IP.
ATNF ticker and transition to ETHZ
Press releases note that the company, doing business as ETHZilla, plans to rebrand formally as ETHZilla Corporation and that its common stock and public warrants will begin trading on the Nasdaq Capital Market under the new ticker symbols ETHZ and ETHZW, replacing the previous symbols ATNF and ANTFW. For users researching ATNF, this means that historical information under ATNF relates to 180 Life Sciences and its transformation, while current and future trading and disclosures may appear under ETHZ.
Legacy biotech focus areas
In earlier descriptions and subsequent IP-related announcements, the company has described work and intellectual property in:
- Inflammatory diseases and fibrosis: Including anti-TNF platforms and approaches to localized fibrotic disorders such as Dupuytren's Disease and Frozen Shoulder.
- Neuroinflammation and post-operative cognitive decline: Methods and agents aimed at preventing or reducing cognitive impairment following surgery or other inflammatory triggers, including use of anti-TNF monoclonal antibodies.
These legacy assets are characterized by the company as potential contributors to long-term shareholder value, even as operational focus shifts toward gaming and Ethereum-related activities.
Sector classification
In industry classification terms, ATNF has been associated with pharmaceutical preparation manufacturing within the broader manufacturing sector, reflecting its biotechnology origins. However, company communications also describe a pivot to the international entertainment and iGaming sector and the development of an ETH-focused treasury strategy, so the business profile spans biotechnology, gaming technology, and digital asset treasury management.
FAQs about ATNF / 180 Life Sciences / ETHZilla
Stock Performance
180 Life Sciences (ATNF) stock last traded at $7.04. Over the past 12 months, the stock has gained 264.8%. At a market capitalization of $1.1B, ATNF is classified as a small-cap stock with approximately 154.0M shares outstanding.
Latest News
180 Life Sciences has 10 recent news articles. Of the recent coverage, 5 articles coincided with positive price movement and 3 with negative movement. Key topics include crypto, private placement, offering, buybacks. View all ATNF news →
SEC Filings
Financial Highlights
operating income reached -$6.3M, and net income was -$6.2M. Diluted earnings per share stood at $-15.49. The company generated -$1.5M in operating cash flow. With a current ratio of 1.47, the company maintains adequate short-term liquidity.
Upcoming Events
Share repurchase completion deadline
Voting agreement expiry
180 Life Sciences has 2 upcoming scheduled events. The next event, "Share repurchase completion deadline", is scheduled for April 1, 2026 (in 8 days). 1 of the upcoming events are financial in nature, such as earnings calls or quarterly results. Investors can track these dates to stay informed about potential catalysts that may affect the ATNF stock price.
Short Interest History
Short interest in 180 Life Sciences (ATNF) currently stands at 6.9 million shares, up 503.9% from the previous reporting period, representing 4.6% of the float. Over the past 12 months, short interest has increased by 11868%. This relatively low short interest suggests limited bearish sentiment.
Days to Cover History
Days to cover for 180 Life Sciences (ATNF) currently stands at 1.0 days. This low days-to-cover ratio indicates high liquidity, allowing short sellers to quickly exit positions if needed. The days to cover has decreased 49.7% over the past year, suggesting improved liquidity for short covering. The ratio has shown significant volatility over the period, ranging from 1.0 to 2.7 days.
ATNF Company Profile & Sector Positioning
180 Life Sciences (ATNF) operates in the Biotechnology industry within the broader Pharmaceutical Preparations sector and is listed on the NASDAQ.
Investors comparing ATNF often look at related companies in the same sector, including Oric Pharmaceuticals, Inc. (ORIC), Atai Beckley Inc (ATAI), Rapport Therapeutics Inc (RAPP), Mimedx Group Inc (MDXG), and Maravai Lifesciences Holdings, Inc. (MRVI). Comparing financial metrics, valuation ratios, and stock performance across these peers can help investors evaluate ATNF's relative position within its industry.